HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 167 filers reported holding HALOZYME THERAPEUTICS INC in Q2 2016. The put-call ratio across all filers is 0.19 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $48,435,000 | +8.1% | 1,066,609 | -0.7% | 0.05% | -1.9% |
| Q1 2021 | $44,799,000 | -38.9% | 1,074,565 | -37.4% | 0.05% | -43.8% |
| Q4 2020 | $73,292,000 | +12.7% | 1,716,047 | -30.6% | 0.10% | -5.9% |
| Q3 2020 | $65,015,000 | -17.8% | 2,473,937 | -16.2% | 0.10% | -25.0% |
| Q2 2020 | $79,108,000 | +146.4% | 2,950,689 | +65.4% | 0.14% | +97.1% |
| Q1 2020 | $32,102,000 | -36.9% | 1,784,468 | -37.8% | 0.07% | -23.3% |
| Q4 2019 | $50,866,000 | -45.7% | 2,868,926 | -52.5% | 0.09% | -8.2% |
| Q3 2019 | $93,596,000 | +46.8% | 6,034,612 | +62.6% | 0.10% | -29.0% |
| Q2 2019 | $63,773,000 | +1.5% | 3,712,062 | -4.9% | 0.14% | 0.0% |
| Q1 2019 | $62,815,000 | +15.5% | 3,901,571 | +5.0% | 0.14% | +1.5% |
| Q4 2018 | $54,362,000 | -11.2% | 3,715,808 | +10.3% | 0.14% | +5.4% |
| Q3 2018 | $61,199,000 | +37.4% | 3,368,134 | +27.5% | 0.13% | +20.6% |
| Q2 2018 | $44,550,000 | -7.9% | 2,640,762 | +7.0% | 0.11% | -10.1% |
| Q1 2018 | $48,355,000 | -2.7% | 2,468,328 | +0.6% | 0.12% | -7.0% |
| Q4 2017 | $49,708,000 | +51.5% | 2,453,502 | +29.9% | 0.13% | +37.6% |
| Q3 2017 | $32,802,000 | +79.5% | 1,888,426 | +21.9% | 0.09% | +66.1% |
| Q2 2017 | $18,274,000 | -3.3% | 1,548,625 | +6.3% | 0.06% | -9.7% |
| Q1 2017 | $18,888,000 | +1270.7% | 1,457,426 | +1177.8% | 0.06% | +1140.0% |
| Q3 2016 | $1,378,000 | +20.1% | 114,053 | 0.0% | 0.01% | +25.0% |
| Q2 2016 | $1,147,000 | +235.4% | 114,053 | +170.9% | 0.00% | +100.0% |
| Q1 2016 | $342,000 | -93.5% | 42,100 | -86.1% | 0.00% | -90.9% |
| Q4 2015 | $5,265,000 | +41.6% | 303,800 | +9.8% | 0.02% | +37.5% |
| Q3 2015 | $3,717,000 | -33.5% | 276,800 | +15.6% | 0.02% | -30.4% |
| Q2 2015 | $5,590,000 | -20.5% | 239,500 | -49.4% | 0.02% | -20.7% |
| Q1 2015 | $7,033,000 | +24.9% | 472,930 | -18.9% | 0.03% | +16.0% |
| Q4 2014 | $5,631,000 | +97.3% | 583,475 | +86.1% | 0.02% | +78.6% |
| Q3 2014 | $2,854,000 | -6.4% | 313,600 | +1.6% | 0.01% | -6.7% |
| Q2 2014 | $3,049,000 | -21.1% | 308,600 | +1.4% | 0.02% | -21.1% |
| Q1 2014 | $3,865,000 | -18.7% | 304,300 | -4.0% | 0.02% | -20.8% |
| Q4 2013 | $4,753,000 | +47.4% | 317,100 | +8.6% | 0.02% | +33.3% |
| Q3 2013 | $3,224,000 | +75.0% | 292,000 | +25.9% | 0.02% | +63.6% |
| Q2 2013 | $1,842,000 | – | 232,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
| BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
| SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
| SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
| Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
| MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
| DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
| Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |
| Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |